Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 47(6); 2023 > Article
Response
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Nikolai N. Scherbak1*, Robert Kruse2,3*, Thomas Nyström4, Johan Jendle5orcid
Diabetes & Metabolism Journal 2023;47(6):882-883.
DOI: https://doi.org/10.4093/dmj.2023.0355
Published online: November 24, 2023
  • 742 Views
  • 23 Download

1Life Science Center, Örebro University, School of Science and Technology, Örebro, Sweden

2Department of Clinical Research Laboratory, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

3Inflammatory Response and Infection Susceptibility Center (iRiSC), Faculty of Medicine and Health, Örebro University, Örebro, Sweden

4Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden

5School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

Corresponding author: Johan Jendle orcid School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-70182 Örebro, Sweden E-mail: johan.jendle@oru.se
*Nikolai N. Scherbak and Robert Kruse contributed equally to this study as first authors.

Copyright © 2023 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

See the letter "Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)" on page 879.
We appreciate Dr. Lee’s insightful comments regarding our recently published article, titled “Glimepiride compared to liraglutide increases plasma levels of miR-206, miR-182-5p, and miR-766-3p in type 2 diabetes mellitus: a randomized controlled trial [1].” The growing body of evidence suggests that microRNAs (miRNAs) play a significant role in the pathogenesis of type 2 diabetes mellitus (T2DM) [2,3]. Nevertheless, only a limited number of studies have explored variations in miRNA expression in response to glucose-lowering drugs [4].
It is crucial to recognize that the miRNAs identified in our study (miR-206, miR-182-5p, and miR-766-3p) have previously been proposed as biomarkers for various diseases apart from T2DM [5-9]. That is why it is essential to notice that the expression of these miRNAs is not solely specific to a particular disease but can also be influenced by medical treatments, such as glimepiride. Thus, investigations about the effect of glucoselowering drugs on miRNAs’ expression are of importance in our understanding of the molecular mechanisms underpinning the actions of these drugs and in shaping personalized treatment strategies.
It is also important to clarify that the aim of our study was not to suggest biomarkers and therefore did not have the design needed to generalize and validate findings outside of our study population [10]. As stated in the conclusion, we see a future need to evaluate miRNAs as potential biomarkers, or biosignatures. In relation to our findings, we see a need for further research to evaluate miR-206, miR-182-5p, and miR-766-3p in the context of diagnosis, prognosis and therapy response of T2DM.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

  • 1. Scherbak NN, Kruse R, Nystrom T, Jendle J. Glimepiride compared to liraglutide increases plasma levels of miR-206, miR-182-5p, and miR-766-3p in type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J 2023;47:668-81.ArticlePubMedPMCPDF
  • 2. Barbagallo D, Piro S, Condorelli AG, Mascali LG, Urbano F, Parrinello N, et al. miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells. BMC Genomics 2013;14:62.ArticlePubMedPMCPDF
  • 3. Guay C, Regazzi R. New emerging tasks for microRNAs in the control of β-cell activities. Biochim Biophys Acta 2016;1861(12 Pt B):2121-9.ArticlePubMed
  • 4. Demirsoy IH, Ertural DY, Balci S, Cinkir U, Sezer K, Tamer L, et al. Profiles of circulating miRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem 2018;37:499-506.ArticlePubMedPMC
  • 5. Li X, Li Y, Zhao L, Zhang D, Yao X, Zhang H, et al. Circulating muscle-specific miRNAs in Duchenne muscular dystrophy patients. Mol Ther Nucleic Acids 2014;3:e177.ArticlePubMedPMC
  • 6. Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, Osta R. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One 2014;9:e89065.ArticlePubMedPMC
  • 7. Liu X, Zheng W, Zhang X, Dong M, Sun G. The diagnostic and prognostic value of serum miR-206 in colorectal cancer. Int J Clin Exp Pathol 2017;10:7528-33. 8. Jin P, Gu W, Lai Y, Zheng W, Zhou Q, Wu X. The circulating microRNA-206 level predicts the severity of pulmonary hypertension in patients with left heart diseases. Cell Physiol Biochem 2017;41:2150-60.ArticlePubMedPDF
  • 9. Zhu L, Chen T, Ye W, Wang JY, Zhou JP, Li ZY, et al. Circulating miR-182-5p and miR-5187-5p as biomarkers for the diagnosis of unprotected left main coronary artery disease. J Thorac Dis 2019;11:1799-808.ArticlePubMedPMC
  • 10. FDA Center for Drug Evaluation and Research. Biomarker qualification: evidentiary framework (FDA-2018-D-4267). Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework (cited 2023 Oct 12).

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
        Diabetes Metab J. 2023;47(6):882-883.   Published online November 24, 2023
        Close
      • XML DownloadXML Download
      Related articles
      Scherbak NN, Kruse R, Nyström T, Jendle J. Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81). Diabetes Metab J. 2023;47(6):882-883.
      DOI: https://doi.org/10.4093/dmj.2023.0355.

      Diabetes Metab J : Diabetes & Metabolism Journal